The article argues that while ayahuasca has shown promise in early depression research, the field must move beyond initial enthusiasm to address methodological challenges and ethical considerations. It calls for rigorous, well-controlled studies to determine efficacy and safety, and emphasizes the need to understand the specific mechanisms of action. The authors suggest that future research should focus on long-term outcomes, potential risks, and the integration of ayahuasca into broader therapeutic contexts, rather than simply celebrating its potential.
A derivative of the hallucinogen salvinorin A, called 22-azidosalvinorin A (SA2), shows antidepressant-like effects in mice. Oral treatment with SA2 at doses of 5, 10, and 20 mg/kg reduced immobility in the forced swimming test and tail suspension test without affecting general locomotion, indicating an antidepressant-like property. This effect was not blocked by serotonin depletion or a 5-HT1A receptor antagonist, but was blocked by depleting catecholamines or blocking α1-adrenoceptors. SA2 mildly inhibited monoamine oxidase and showed affinity for α1A, α1B, α1D, and κ-opioid receptor subtypes, suggesting its antidepressant-like action is mediated through monoamine systems.